ID   DNM3A_HUMAN             Reviewed;         912 AA.
AC   Q9Y6K1; E9PEB8; Q86TE8; Q86XF5; Q8IZV0; Q8WXU9;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 4.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=DNA (cytosine-5)-methyltransferase 3A;
DE            Short=Dnmt3a;
DE            EC=2.1.1.37;
DE   AltName: Full=DNA methyltransferase HsaIIIA;
DE            Short=DNA MTase HsaIIIA;
DE            Short=M.HsaIIIA;
GN   Name=DNMT3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal testis;
RX   PubMed=10433969; DOI=10.1016/S0378-1119(99)00252-8;
RA   Xie S., Wang Z., Okano M., Nogami M., Li Y., He W.-W., Okumura K.,
RA   Li E.;
RT   "Cloning, expression and chromosome locations of the human DNMT3 gene
RT   family.";
RL   Gene 236:87-95(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12138111; DOI=10.1074/jbc.M205312200;
RA   Chen T., Ueda Y., Xie S., Li E.;
RT   "A novel Dnmt3a isoform produced from an alternative promoter
RT   localizes to euchromatin and its expression correlates with active de
RT   novo methylation.";
RL   J. Biol. Chem. 277:38746-38754(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH DNMT1 AND
RP   DNMT3B, AND SUBCELLULAR LOCATION.
RX   PubMed=12145218; DOI=10.1093/emboj/cdf401;
RA   Kim G.-D., Ni J., Kelesoglu N., Roberts R.J., Pradhan S.;
RT   "Co-operation and communication between the human maintenance and de
RT   novo DNA (cytosine-5) methyltransferases.";
RL   EMBO J. 21:4183-4195(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung, PNS, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=10325416; DOI=10.1093/nar/27.11.2291;
RA   Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J.,
RA   Gonzales F.A., Jones P.A.;
RT   "The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate
RT   mRNA expression in normal tissues and overexpression in tumors.";
RL   Nucleic Acids Res. 27:2291-2298(1999).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   INTERACTION WITH SETDB1.
RX   PubMed=16682412; DOI=10.1074/jbc.M513249200;
RA   Li H., Rauch T., Chen Z.-X., Szabo P.E., Riggs A.D., Pfeifer G.P.;
RT   "The histone methyltransferase SETDB1 and the DNA methyltransferase
RT   DNMT3A interact directly and localize to promoters silenced in cancer
RT   cells.";
RL   J. Biol. Chem. 281:19489-19500(2006).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH THE PRC2/EED-EZH2 COMPLEX.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [11]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [12]
RP   DE NOVO DNA METHYLATION OF TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   INTERACTION WITH MPHOSPH8.
RX   PubMed=20871592; DOI=10.1038/emboj.2010.239;
RA   Kokura K., Sun L., Bedford M.T., Fang J.;
RT   "Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing
RT   and promotes tumour cell motility and invasion.";
RL   EMBO J. 29:3673-3687(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-243, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; SER-243; SER-255;
RP   THR-261 AND SER-267, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   INVOLVEMENT IN TBRS, AND VARIANTS TBRS ASN-310; SER-532; LYS-548;
RP   ARG-549; PRO-648; LEU-700; CYS-749; ASP-838; SER-902 AND LEU-904.
RX   PubMed=24614070; DOI=10.1038/ng.2917;
RG   Childhood Overgrowth Consortium;
RA   Tatton-Brown K., Seal S., Ruark E., Harmer J., Ramsay E.,
RA   Del Vecchio Duarte S., Zachariou A., Hanks S., O'Brien E.,
RA   Aksglaede L., Baralle D., Dabir T., Gener B., Goudie D., Homfray T.,
RA   Kumar A., Pilz D.T., Selicorni A., Temple I.K., Van Maldergem L.,
RA   Yachelevich N., van Montfort R., Rahman N.;
RT   "Mutations in the DNA methyltransferase gene DNMT3A cause an
RT   overgrowth syndrome with intellectual disability.";
RL   Nat. Genet. 46:385-388(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.89 ANGSTROMS) OF 627-909 IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE, SUBUNIT, AND MUTAGENESIS OF PHE-732.
RX   PubMed=17713477; DOI=10.1038/nature06146;
RA   Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X.;
RT   "Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA
RT   methylation.";
RL   Nature 449:248-251(2007).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.29 ANGSTROMS) OF 476-614 IN COMPLEXES WITH
RP   ZINC AND WITH HISTONE H3 PEPTIDE, AND SUBUNIT.
RX   PubMed=19834512; DOI=10.1038/embor.2009.218;
RA   Otani J., Nankumo T., Arita K., Inamoto S., Ariyoshi M., Shirakawa M.;
RT   "Structural basis for recognition of H3K4 methylation status by the
RT   DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain.";
RL   EMBO Rep. 10:1235-1241(2009).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS) OF 40-53 IN COMPLEX WITH
RP   MPHOSPH8, AND INTERACTION WITH MPHOSPH8.
RX   PubMed=22086334; DOI=10.1038/ncomms1549;
RA   Chang Y., Sun L., Kokura K., Horton J.R., Fukuda M., Espejo A.,
RA   Izumi V., Koomen J.M., Bedford M.T., Zhang X., Shinkai Y., Fang J.,
RA   Cheng X.;
RT   "MPP8 mediates the interactions between DNA methyltransferase Dnmt3a
RT   and H3K9 methyltransferase GLP/G9a.";
RL   Nat. Commun. 2:533-533(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 275-427.
RX   PubMed=21720545; DOI=10.1371/journal.pone.0018919;
RA   Wu H., Zeng H., Lam R., Tempel W., Amaya M.F., Xu C., Dombrovski L.,
RA   Qiu W., Wang Y., Min J.;
RT   "Structural and histone binding ability characterizations of human
RT   PWWP domains.";
RL   PLoS ONE 6:E18919-E18919(2011).
RN   [23]
RP   VARIANTS ASP-699; PHE-731 DEL; CYS-882; HIS-882 AND PRO-882.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y.,
RA   Traina F., Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D.,
RA   List A., Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia
RT   includes genes associated with epigenetic regulation: UTX, EZH2, and
RT   DNMT3A.";
RL   Blood 118:3932-3941(2011).
RN   [24]
RP   VARIANT TBRS GLN-771.
RX   PubMed=27701732; DOI=10.1111/cge.12878;
RA   Xin B., Cruz Marino T., Szekely J., Leblanc J., Cechner K., Sency V.,
RA   Wensel C., Barabas M., Therriault V., Wang H.;
RT   "Novel DNMT3A germline mutations are associated with inherited Tatton-
RT   Brown-Rahman syndrome.";
RL   Clin. Genet. 91:623-628(2017).
RN   [25]
RP   VARIANTS TBRS CYS-365; ASN-529; GLY-778 AND CYS-882.
RX   PubMed=27317772; DOI=10.1136/jmedgenet-2015-103638;
RA   Tlemsani C., Luscan A., Leulliot N., Bieth E., Afenjar A., Baujat G.,
RA   Doco-Fenzy M., Goldenberg A., Lacombe D., Lambert L., Odent S.,
RA   Pasche J., Sigaudy S., Buffet A., Violle-Poirsier C.,
RA   Briand-Suleau A., Laurendeau I., Chin M., Saugier-Veber P., Vidaud D.,
RA   Cormier-Daire V., Vidaud M., Pasmant E., Burglen L.;
RT   "SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort.";
RL   J. Med. Genet. 0:0-0(2016).
CC   -!- FUNCTION: Required for genome-wide de novo methylation and is
CC       essential for the establishment of DNA methylation patterns during
CC       development. DNA methylation is coordinated with methylation of
CC       histones. It modifies DNA in a non-processive manner and also
CC       methylates non-CpG sites. May preferentially methylate DNA linker
CC       between 2 nucleosomal cores and is inhibited by histone H1. Plays
CC       a role in paternal and maternal imprinting. Required for
CC       methylation of most imprinted loci in germ cells. Acts as a
CC       transcriptional corepressor for ZBTB18. Recruited to trimethylated
CC       'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress
CC       transcription through the recruitment of HDAC activity.
CC       {ECO:0000269|PubMed:16357870}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + DNA = S-adenosyl-L-
CC       homocysteine + DNA containing 5-methylcytosine.
CC       {ECO:0000255|PROSITE-ProRule:PRU10018}.
CC   -!- ENZYME REGULATION: Activated by binding to the regulatory factor
CC       DNMT3L. {ECO:0000250}.
CC   -!- SUBUNIT: Heterotetramer composed of 1 DNMT3A homodimer and 2
CC       DNMT3L subunits (DNMT3L-DNMT3A-DNMT3A-DNMT3L). Interacts with
CC       UBC9, PIAS1 and PIAS2 (By similarity). Binds the ZBTB18
CC       transcriptional repressor. Interacts with SETDB1. Associates with
CC       HDAC1 through its ADD domain. Interacts with UHRF1 (By
CC       similarity). Interacts with DNMT1 and DNMT3B. Interacts with the
CC       PRC2/EED-EZH2 complex. Interacts with MPHOSPH8. Interacts with
CC       histone H3 that is not methylated at 'Lys-4' (H3K4). {ECO:0000250,
CC       ECO:0000269|PubMed:12145218, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:16682412, ECO:0000269|PubMed:17713477,
CC       ECO:0000269|PubMed:19834512, ECO:0000269|PubMed:20871592,
CC       ECO:0000269|PubMed:22086334}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-923653, EBI-923653;
CC       Q03060:CREM; NbExp=2; IntAct=EBI-923653, EBI-3907794;
CC       O75530:EED; NbExp=2; IntAct=EBI-923653, EBI-923794;
CC       Q15910:EZH2; NbExp=6; IntAct=EBI-923653, EBI-530054;
CC       P84243:H3F3B; NbExp=7; IntAct=EBI-923653, EBI-120658;
CC       Q15047:SETDB1; NbExp=7; IntAct=EBI-923653, EBI-79691;
CC       P23497:SP100; NbExp=3; IntAct=EBI-923653, EBI-751145;
CC       P56279:TCL1A; NbExp=5; IntAct=EBI-923653, EBI-749995;
CC       Q96T88:UHRF1; NbExp=7; IntAct=EBI-923653, EBI-1548946;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12145218}.
CC       Cytoplasm {ECO:0000269|PubMed:12145218}. Note=Accumulates in the
CC       major satellite repeats at pericentric heterochromatin.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9Y6K1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y6K1-2; Sequence=VSP_046254;
CC         Note=It is uncertain whether Met-1 or Met-35 is the initiator.;
CC       Name=3;
CC         IsoId=Q9Y6K1-3; Sequence=VSP_040998, VSP_040999;
CC         Note=Produced by alternative splicing.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal tissues, skeletal
CC       muscle, heart, peripheral blood mononuclear cells, kidney, and at
CC       lower levels in placenta, brain, liver, colon, spleen, small
CC       intestine and lung. {ECO:0000269|PubMed:10325416}.
CC   -!- DOMAIN: The PWWP domain is essential for targeting to pericentric
CC       heterochromatin. It specifically recognizes and binds
CC       trimethylated 'Lys-36' of histone H3 (H3K36me3) (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylated; sumoylation disrupts the ability to interact with
CC       histone deacetylases (HDAC1 and HDAC2) and repress transcription.
CC       {ECO:0000250}.
CC   -!- DISEASE: Tatton-Brown-Rahman syndrome (TBRS) [MIM:615879]: An
CC       overgrowth syndrome characterized by a distinctive facial
CC       appearance, tall stature and intellectual disability. Facial
CC       gestalt is characterized by a round face, heavy horizontal
CC       eyebrows and narrow palpebral fissures. Less common features
CC       include atrial septal defects, seizures, umbilical hernia, and
CC       scoliosis. {ECO:0000269|PubMed:24614070,
CC       ECO:0000269|PubMed:27317772, ECO:0000269|PubMed:27701732}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. C5-methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01016}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL57039.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAN40037.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF067972; AAD33084.2; -; mRNA.
DR   EMBL; AF480163; AAN40037.1; ALT_INIT; mRNA.
DR   EMBL; AF331856; AAL57039.1; ALT_INIT; mRNA.
DR   EMBL; AC012074; AAY14761.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00727.1; -; Genomic_DNA.
DR   EMBL; BC032392; AAH32392.1; -; mRNA.
DR   EMBL; BC043617; AAH43617.1; -; mRNA.
DR   EMBL; BC051864; AAH51864.1; -; mRNA.
DR   CCDS; CCDS1718.2; -. [Q9Y6K1-2]
DR   CCDS; CCDS33157.1; -. [Q9Y6K1-1]
DR   CCDS; CCDS46232.1; -. [Q9Y6K1-3]
DR   RefSeq; NP_001307821.1; NM_001320892.1. [Q9Y6K1-3]
DR   RefSeq; NP_001307822.1; NM_001320893.1.
DR   RefSeq; NP_072046.2; NM_022552.4. [Q9Y6K1-1]
DR   RefSeq; NP_715640.2; NM_153759.3. [Q9Y6K1-2]
DR   RefSeq; NP_783328.1; NM_175629.2. [Q9Y6K1-1]
DR   RefSeq; NP_783329.1; NM_175630.1. [Q9Y6K1-3]
DR   RefSeq; XP_005264232.1; XM_005264175.4. [Q9Y6K1-1]
DR   RefSeq; XP_005264234.1; XM_005264177.4.
DR   RefSeq; XP_011530969.1; XM_011532667.2.
DR   RefSeq; XP_016859015.1; XM_017003526.1. [Q9Y6K1-1]
DR   RefSeq; XP_016859016.1; XM_017003527.1.
DR   UniGene; Hs.515840; -.
DR   PDB; 2QRV; X-ray; 2.89 A; A/D/E/H=627-912.
DR   PDB; 3A1A; X-ray; 2.30 A; A=476-614.
DR   PDB; 3A1B; X-ray; 2.29 A; A=476-614.
DR   PDB; 3LLR; X-ray; 2.30 A; A/B/C/D/E=275-427.
DR   PDB; 3SVM; X-ray; 2.31 A; P=40-53.
DR   PDB; 4QBQ; X-ray; 2.41 A; A/C=479-610.
DR   PDB; 4QBR; X-ray; 1.90 A; A/C=476-611.
DR   PDB; 4QBS; X-ray; 1.80 A; A=476-611.
DR   PDB; 4U7P; X-ray; 3.82 A; A=455-912.
DR   PDB; 4U7T; X-ray; 2.90 A; A/C=476-912.
DR   PDBsum; 2QRV; -.
DR   PDBsum; 3A1A; -.
DR   PDBsum; 3A1B; -.
DR   PDBsum; 3LLR; -.
DR   PDBsum; 3SVM; -.
DR   PDBsum; 4QBQ; -.
DR   PDBsum; 4QBR; -.
DR   PDBsum; 4QBS; -.
DR   PDBsum; 4U7P; -.
DR   PDBsum; 4U7T; -.
DR   ProteinModelPortal; Q9Y6K1; -.
DR   SMR; Q9Y6K1; -.
DR   BioGrid; 108125; 53.
DR   DIP; DIP-38004N; -.
DR   IntAct; Q9Y6K1; 28.
DR   STRING; 9606.ENSP00000264709; -.
DR   BindingDB; Q9Y6K1; -.
DR   ChEMBL; CHEMBL1992; -.
DR   REBASE; 4119; M.HsaDnmt3A.
DR   iPTMnet; Q9Y6K1; -.
DR   PhosphoSitePlus; Q9Y6K1; -.
DR   BioMuta; DNMT3A; -.
DR   DMDM; 166215081; -.
DR   EPD; Q9Y6K1; -.
DR   PaxDb; Q9Y6K1; -.
DR   PeptideAtlas; Q9Y6K1; -.
DR   PRIDE; Q9Y6K1; -.
DR   DNASU; 1788; -.
DR   Ensembl; ENST00000264709; ENSP00000264709; ENSG00000119772. [Q9Y6K1-1]
DR   Ensembl; ENST00000321117; ENSP00000324375; ENSG00000119772. [Q9Y6K1-1]
DR   Ensembl; ENST00000380746; ENSP00000370122; ENSG00000119772. [Q9Y6K1-2]
DR   Ensembl; ENST00000406659; ENSP00000384852; ENSG00000119772. [Q9Y6K1-3]
DR   GeneID; 1788; -.
DR   KEGG; hsa:1788; -.
DR   UCSC; uc002rgb.5; human. [Q9Y6K1-1]
DR   CTD; 1788; -.
DR   DisGeNET; 1788; -.
DR   GeneCards; DNMT3A; -.
DR   HGNC; HGNC:2978; DNMT3A.
DR   HPA; CAB009469; -.
DR   HPA; HPA026588; -.
DR   MalaCards; DNMT3A; -.
DR   MIM; 602769; gene.
DR   MIM; 615879; phenotype.
DR   neXtProt; NX_Q9Y6K1; -.
DR   OpenTargets; ENSG00000119772; -.
DR   Orphanet; 404443; Tall stature-intellectual disability-facial dysmorphism syndrome.
DR   PharmGKB; PA27445; -.
DR   eggNOG; ENOG410IGHW; Eukaryota.
DR   eggNOG; ENOG410XQ4Y; LUCA.
DR   GeneTree; ENSGT00390000008341; -.
DR   HOGENOM; HOG000230875; -.
DR   HOVERGEN; HBG051381; -.
DR   InParanoid; Q9Y6K1; -.
DR   KO; K17398; -.
DR   OMA; YTEMWVE; -.
DR   OrthoDB; EOG091G01TP; -.
DR   PhylomeDB; Q9Y6K1; -.
DR   TreeFam; TF329039; -.
DR   BRENDA; 2.1.1.37; 2681.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-3214858; RMTs methylate histone arginines.
DR   Reactome; R-HSA-5334118; DNA methylation.
DR   SIGNOR; Q9Y6K1; -.
DR   ChiTaRS; DNMT3A; human.
DR   EvolutionaryTrace; Q9Y6K1; -.
DR   GenomeRNAi; 1788; -.
DR   PRO; PR:Q9Y6K1; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000119772; -.
DR   CleanEx; HS_DNMT3A; -.
DR   ExpressionAtlas; Q9Y6K1; baseline and differential.
DR   Genevisible; Q9Y6K1; HS.
DR   GO; GO:0000775; C:chromosome, centromeric region; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000791; C:euchromatin; IDA:UniProtKB.
DR   GO; GO:0005720; C:nuclear heterochromatin; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0001741; C:XY body; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003886; F:DNA (cytosine-5-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0009008; F:DNA-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006306; P:DNA methylation; IDA:UniProtKB.
DR   GO; GO:0043045; P:DNA methylation involved in embryo development; IEA:Ensembl.
DR   GO; GO:0043046; P:DNA methylation involved in gamete generation; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0006346; P:methylation-dependent chromatin silencing; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0010942; P:positive regulation of cell death; IEA:Ensembl.
DR   GO; GO:0006349; P:regulation of gene expression by genetic imprinting; TAS:UniProtKB.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0033189; P:response to vitamin A; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   InterPro; IPR025766; ADD.
DR   InterPro; IPR018117; C5_DNA_meth_AS.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR030487; DNMT3A.
DR   InterPro; IPR000313; PWWP_dom.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PANTHER; PTHR23068:SF17; PTHR23068:SF17; 1.
DR   Pfam; PF00145; DNA_methylase; 1.
DR   Pfam; PF00855; PWWP; 1.
DR   SMART; SM00293; PWWP; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51533; ADD; 1.
DR   PROSITE; PS00094; C5_MTASE_1; 1.
DR   PROSITE; PS50812; PWWP; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Chromatin regulator; Complete proteome; Cytoplasm; Disease mutation;
KW   DNA-binding; Mental retardation; Metal-binding; Methylation;
KW   Methyltransferase; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; S-adenosyl-L-methionine; Transferase;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    912       DNA (cytosine-5)-methyltransferase 3A.
FT                                /FTId=PRO_0000088043.
FT   DOMAIN      292    350       PWWP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00162}.
FT   DOMAIN      482    614       ADD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   DOMAIN      634    912       SAM-dependent MTase C5-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01016}.
FT   ZN_FING     493    523       GATA-type; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00865}.
FT   ZN_FING     534    590       PHD-type; atypical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   REGION      199    403       Interaction with DNMT1 and DNMT3B.
FT                                {ECO:0000269|PubMed:12145218}.
FT   REGION      494    586       Interaction with the PRC2/EED-EZH2
FT                                complex. {ECO:0000250}.
FT   REGION      641    645       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000244|PDB:2QRV,
FT                                ECO:0000269|PubMed:17713477}.
FT   REGION      686    688       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000244|PDB:2QRV,
FT                                ECO:0000269|PubMed:17713477}.
FT   REGION      891    893       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000244|PDB:2QRV,
FT                                ECO:0000269|PubMed:17713477}.
FT   ACT_SITE    710    710       {ECO:0000255|PROSITE-ProRule:PRU01016,
FT                                ECO:0000255|PROSITE-ProRule:PRU10018}.
FT   BINDING     664    664       S-adenosyl-L-homocysteine.
FT                                {ECO:0000244|PDB:2QRV,
FT                                ECO:0000269|PubMed:17713477}.
FT   MOD_RES     105    105       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     124    124       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q1LZ53}.
FT   MOD_RES     171    171       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:O88508}.
FT   MOD_RES     243    243       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     255    255       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     261    261       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     267    267       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     390    390       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88508}.
FT   MOD_RES     393    393       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88508}.
FT   VAR_SEQ       1    213       MPAMPSSGPGDTSSSAAEREEDRKDGEEQEEPRGKEERQEP
FT                                STTARKVGRPGRKRKHPPVESGDTPKDPAVISKSPSMAQDS
FT                                GASELLPNGDLEKRSEPQPEEGSPAGGQKGGAPAEGEGAAE
FT                                TLPEASRAVENGCCTPKEGRGAPAEAGKEQKETNIESMKME
FT                                GSRGRLRGGLGWESSLRQRPMPRLTFQAGDPYYISKRKRDE
FT                                WLARWKRE -> MGILERVVRRNGRVDRSLKDECDT (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:12138111}.
FT                                /FTId=VSP_046254.
FT   VAR_SEQ     151    166       KEQKETNIESMKMEGS -> ESSAPGAASSGPTSIP (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_040998.
FT   VAR_SEQ     167    912       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_040999.
FT   VARIANT     310    310       I -> N (in TBRS; somatic mutation;
FT                                dbSNP:rs587777508).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071463.
FT   VARIANT     365    365       Y -> C (in TBRS; unknown pathological
FT                                significance; dbSNP:rs144062658).
FT                                {ECO:0000269|PubMed:27317772}.
FT                                /FTId=VAR_077522.
FT   VARIANT     529    529       D -> N (in TBRS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27317772}.
FT                                /FTId=VAR_077523.
FT   VARIANT     532    532       G -> S (in TBRS; somatic mutation).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071464.
FT   VARIANT     548    548       M -> K (in TBRS; somatic mutation;
FT                                dbSNP:rs587777509).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071465.
FT   VARIANT     549    549       C -> R (in TBRS; somatic mutation).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071466.
FT   VARIANT     648    648       L -> P (in TBRS; somatic mutation;
FT                                dbSNP:rs587777507).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071467.
FT   VARIANT     699    699       G -> D (in a patient with chronic
FT                                myelomonocytic leukemia;
FT                                dbSNP:rs761064473).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067234.
FT   VARIANT     700    700       P -> L (in TBRS; somatic mutation;
FT                                dbSNP:rs772368909).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071468.
FT   VARIANT     731    731       Missing (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067235.
FT   VARIANT     749    749       R -> C (in TBRS; somatic mutation;
FT                                dbSNP:rs754613602).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071469.
FT   VARIANT     771    771       R -> Q (in TBRS; unknown pathological
FT                                significance; dbSNP:rs757823678).
FT                                {ECO:0000269|PubMed:27701732}.
FT                                /FTId=VAR_077524.
FT   VARIANT     778    778       V -> G (in TBRS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27317772}.
FT                                /FTId=VAR_077525.
FT   VARIANT     838    838       N -> D (in TBRS; somatic mutation).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071470.
FT   VARIANT     882    882       R -> C (in a patient with chronic
FT                                myelomonocytic leukemia; somatic
FT                                mutation; dbSNP:rs377577594).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067236.
FT   VARIANT     882    882       R -> H (in a patient with chronic
FT                                myelomonocytic leukemia; somatic
FT                                mutation; dbSNP:rs147001633).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067237.
FT   VARIANT     882    882       R -> P (in a patient with chronic
FT                                myelomonocytic leukemia; somatic
FT                                mutation; dbSNP:rs147001633).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067238.
FT   VARIANT     902    902       F -> S (in TBRS; somatic mutation;
FT                                dbSNP:rs587777510).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071471.
FT   VARIANT     904    904       P -> L (in TBRS; somatic mutation;
FT                                dbSNP:rs149095705).
FT                                {ECO:0000269|PubMed:24614070}.
FT                                /FTId=VAR_071472.
FT   MUTAGEN     732    732       F->A: Loss of activity du to the
FT                                incapacity to bind the regulatory subunit
FT                                DNMT3L. {ECO:0000269|PubMed:17713477}.
FT   STRAND      295    298       {ECO:0000244|PDB:3LLR}.
FT   STRAND      306    311       {ECO:0000244|PDB:3LLR}.
FT   HELIX       313    315       {ECO:0000244|PDB:3LLR}.
FT   STRAND      325    330       {ECO:0000244|PDB:3LLR}.
FT   TURN        331    333       {ECO:0000244|PDB:3LLR}.
FT   STRAND      336    340       {ECO:0000244|PDB:3LLR}.
FT   HELIX       341    343       {ECO:0000244|PDB:3LLR}.
FT   STRAND      344    346       {ECO:0000244|PDB:3LLR}.
FT   HELIX       347    349       {ECO:0000244|PDB:3LLR}.
FT   HELIX       350    353       {ECO:0000244|PDB:3LLR}.
FT   HELIX       356    361       {ECO:0000244|PDB:3LLR}.
FT   HELIX       363    380       {ECO:0000244|PDB:3LLR}.
FT   HELIX       393    395       {ECO:0000244|PDB:3LLR}.
FT   HELIX       399    411       {ECO:0000244|PDB:3LLR}.
FT   TURN        415    417       {ECO:0000244|PDB:3LLR}.
FT   HELIX       419    422       {ECO:0000244|PDB:3LLR}.
FT   HELIX       476    484       {ECO:0000244|PDB:4QBS}.
FT   HELIX       490    492       {ECO:0000244|PDB:4QBS}.
FT   TURN        495    497       {ECO:0000244|PDB:4QBS}.
FT   STRAND      502    505       {ECO:0000244|PDB:4QBS}.
FT   STRAND      507    514       {ECO:0000244|PDB:4QBS}.
FT   HELIX       515    524       {ECO:0000244|PDB:4QBS}.
FT   STRAND      532    536       {ECO:0000244|PDB:4QBS}.
FT   TURN        538    540       {ECO:0000244|PDB:4QBS}.
FT   STRAND      544    548       {ECO:0000244|PDB:4QBS}.
FT   TURN        552    554       {ECO:0000244|PDB:4QBR}.
FT   STRAND      557    559       {ECO:0000244|PDB:4QBS}.
FT   HELIX       560    566       {ECO:0000244|PDB:4QBS}.
FT   HELIX       571    577       {ECO:0000244|PDB:4QBS}.
FT   STRAND      578    580       {ECO:0000244|PDB:4QBS}.
FT   TURN        584    586       {ECO:0000244|PDB:4QBS}.
FT   STRAND      587    589       {ECO:0000244|PDB:4QBQ}.
FT   STRAND      595    597       {ECO:0000244|PDB:4QBS}.
FT   HELIX       601    608       {ECO:0000244|PDB:4QBS}.
FT   HELIX       628    630       {ECO:0000244|PDB:4U7T}.
FT   STRAND      634    639       {ECO:0000244|PDB:2QRV}.
FT   TURN        642    644       {ECO:0000244|PDB:2QRV}.
FT   HELIX       645    652       {ECO:0000244|PDB:2QRV}.
FT   STRAND      657    663       {ECO:0000244|PDB:2QRV}.
FT   HELIX       667    676       {ECO:0000244|PDB:2QRV}.
FT   TURN        677    679       {ECO:0000244|PDB:2QRV}.
FT   STRAND      681    684       {ECO:0000244|PDB:2QRV}.
FT   HELIX       687    689       {ECO:0000244|PDB:2QRV}.
FT   HELIX       692    697       {ECO:0000244|PDB:2QRV}.
FT   STRAND      702    706       {ECO:0000244|PDB:2QRV}.
FT   HELIX       711    713       {ECO:0000244|PDB:2QRV}.
FT   TURN        722    724       {ECO:0000244|PDB:2QRV}.
FT   TURN        726    729       {ECO:0000244|PDB:2QRV}.
FT   HELIX       730    741       {ECO:0000244|PDB:2QRV}.
FT   STRAND      752    761       {ECO:0000244|PDB:2QRV}.
FT   HELIX       763    773       {ECO:0000244|PDB:2QRV}.
FT   STRAND      778    781       {ECO:0000244|PDB:4U7T}.
FT   HELIX       782    784       {ECO:0000244|PDB:2QRV}.
FT   STRAND      786    788       {ECO:0000244|PDB:2QRV}.
FT   STRAND      791    796       {ECO:0000244|PDB:2QRV}.
FT   STRAND      801    803       {ECO:0000244|PDB:2QRV}.
FT   HELIX       815    817       {ECO:0000244|PDB:2QRV}.
FT   STRAND      824    830       {ECO:0000244|PDB:2QRV}.
FT   STRAND      850    852       {ECO:0000244|PDB:2QRV}.
FT   STRAND      855    857       {ECO:0000244|PDB:2QRV}.
FT   HELIX       861    868       {ECO:0000244|PDB:2QRV}.
FT   TURN        872    875       {ECO:0000244|PDB:2QRV}.
FT   HELIX       882    890       {ECO:0000244|PDB:2QRV}.
FT   HELIX       895    902       {ECO:0000244|PDB:2QRV}.
FT   HELIX       903    908       {ECO:0000244|PDB:2QRV}.
SQ   SEQUENCE   912 AA;  101858 MW;  BD1FF7C5B4F54A33 CRC64;
     MPAMPSSGPG DTSSSAAERE EDRKDGEEQE EPRGKEERQE PSTTARKVGR PGRKRKHPPV
     ESGDTPKDPA VISKSPSMAQ DSGASELLPN GDLEKRSEPQ PEEGSPAGGQ KGGAPAEGEG
     AAETLPEASR AVENGCCTPK EGRGAPAEAG KEQKETNIES MKMEGSRGRL RGGLGWESSL
     RQRPMPRLTF QAGDPYYISK RKRDEWLARW KREAEKKAKV IAGMNAVEEN QGPGESQKVE
     EASPPAVQQP TDPASPTVAT TPEPVGSDAG DKNATKAGDD EPEYEDGRGF GIGELVWGKL
     RGFSWWPGRI VSWWMTGRSR AAEGTRWVMW FGDGKFSVVC VEKLMPLSSF CSAFHQATYN
     KQPMYRKAIY EVLQVASSRA GKLFPVCHDS DESDTAKAVE VQNKPMIEWA LGGFQPSGPK
     GLEPPEEEKN PYKEVYTDMW VEPEAAAYAP PPPAKKPRKS TAEKPKVKEI IDERTRERLV
     YEVRQKCRNI EDICISCGSL NVTLEHPLFV GGMCQNCKNC FLECAYQYDD DGYQSYCTIC
     CGGREVLMCG NNNCCRCFCV ECVDLLVGPG AAQAAIKEDP WNCYMCGHKG TYGLLRRRED
     WPSRLQMFFA NNHDQEFDPP KVYPPVPAEK RKPIRVLSLF DGIATGLLVL KDLGIQVDRY
     IASEVCEDSI TVGMVRHQGK IMYVGDVRSV TQKHIQEWGP FDLVIGGSPC NDLSIVNPAR
     KGLYEGTGRL FFEFYRLLHD ARPKEGDDRP FFWLFENVVA MGVSDKRDIS RFLESNPVMI
     DAKEVSAAHR ARYFWGNLPG MNRPLASTVN DKLELQECLE HGRIAKFSKV RTITTRSNSI
     KQGKDQHFPV FMNEKEDILW CTEMERVFGF PVHYTDVSNM SRLARQRLLG RSWSVPVIRH
     LFAPLKEYFA CV
//
